CD274 and neoplasm: Pembrolizumab (monoclonal antibody against PD-1) can be used in advanced NSCLC patients in second- (tumor must contain at least 1% of PD-L1-positive tumor cells) or in first-line therapy (tumor must contain at least 50% of PD-L1-positive tumor cells).